...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Translational psychiatry. >Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients
【24h】

Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients

机译：Neuremetabolic of 6和16周与丙酮酮在药物 - 天真的第一集集精神病患者的治疗中的相关性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Antipsychotic medications are the cornerstone of treatment in schizophrenia spectrum disorders. In first-episode psychosis, the recommended time for an antipsychotic medication trial is up to 16 weeks, but the biological correlates of shorter and longer antipsychotic treatment trials in these cohorts remain largely unknown. We enrolled 29 medication-naive first-episode patients (FEP) and 22 matched healthy controls (HC) in this magnetic resonance spectroscopy (MRS) study, examining the levels of combined glutamate and glutamine (commonly referred to as Glx) in the bilateral medial prefrontal cortex (MPFC) with a PRESS sequence (TR/TE?=?2000/80?ms) before initiation of antipsychotic treatment, after 6 and 16 weeks of treatment with risperidone. Data were quantified in 18 HC and 20 FEP at baseline, for 19 HC and 15 FEP at week 6, and for 14 HC and 16 FEP at week 16. At baseline, none of the metabolites differed between groups. Metabolite levels did not change after 6 or 16 weeks of treatment in patients. Our data suggest that metabolite levels do not change after 6 or 16 weeks of treatment with risperidone in FEP. It is possible that our choice of sequence parameters and the limited sample size contributed to negative findings reported here. On the other hand, longer follow-up may be needed to detect treatment-related metabolic changes with MRS. In summary, our study adds to the efforts in better understanding glutamatergic neurometabolism in schizophrenia, especially as it relates to antipsychotic exposure.
机译：抗精神病药是精神分裂症谱系障碍治疗的基石。在第一集精神病中，抗精神病药药物试验的推荐时间长达16周，但这些群组中较短和更长的抗精神病药治疗试验的生物学相关性仍然很大程度上是未知的。在该磁共振光谱（MRS）研究中，我们注册了29名药物 - 幼稚的第一集患者（FEP）和22例匹配的健康对照（HC），检查双侧内侧中谷氨酸组合和谷氨酰胺（通常称为GLX）的水平在启动抗精神病药后的前序列（TR / TE？=Δ2000/ 80℃）的前额叶皮质（MPFC），在6至16周的Risperidone治疗后。数据在18 hC和20 fep在基线中量化，19小时和15周，第6周，第16周，16个HC和16个FEP。在基线时，群体之间没有代谢物不同。患者治疗6或16周后，代谢物水平没有改变。我们的数据表明，在FEP中的Risperidone治疗6周或16周后，代谢物水平不会改变。我们可以选择序列参数和有限的样本大小导致在此报告的负面调查结果。另一方面，可能需要更长的随访以检测与MRS相关的治疗相关的代谢变化。总之，我们的研究增加了更好地理解精神分裂症中的谷氨酸谷氨酸神经变量原因的努力，特别是与抗精神病患者接触有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号